Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 100 Novo Nordisk has delivered sustained double digit growth throughout the last decade Sales growth in local currencies 2006-2015 Sales growth Average growth Operating profit growth in local currencies 2006-2015 Operating profit growth Average growth 30% 30% 20% 10% 0% 2006 20% 12% மயப் 2015 10% 0% changing diabetes 2006 Note: Numbers for 2007 and 2008 are adjusted for the impact of the discontinuation of pulmonary insulin projects; Number for 2015 is adjusted for the non-recurring income related to the partial divestment of NNIT with the dotted component representing this income; average is calculated excluding the effect of the 2015 non-recurring income. 19% 2015 novo nordisk

View entire presentation